Sudarshan Pharma Industries (543828) Q4 24/25 earnings summary

Executive summary

• Audited standalone and consolidated financial results for the year ended 31 March 2025 were approved, with unmodified audit opinions from NGST & Associates.

• The company operates in the specialty chemicals segment, with no reportable segments as per AS-17/Ind AS 108.

Financial highlights

• Standalone revenue from operations for FY25 was ₹50,250.66 lakhs, up from ₹46,556.23 lakhs year-over-year.

• Standalone net profit for FY25 was ₹1,587.70 lakhs, compared to ₹1,135.53 lakhs in FY24.

• Consolidated revenue for FY25 was ₹50,504.84 lakhs, up from ₹46,354.16 lakhs year-over-year.

• Consolidated net profit for FY25 was ₹1,595.52 lakhs, compared to ₹1,145.53 lakhs in FY24.

• Basic EPS (consolidated) for FY25 was ₹0.66, up from ₹0.48 in FY24.

Outlook and guidance

• The company continues to focus on specialty chemicals and has expanded its presence through acquisitions.